Gyre Therapeutics (GYRE) Raw Materials (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Raw Materials data on file, last reported at $1.2 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $1.2 million, changed 0.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (changed 0.43% YoY), and the FY2025 annual result was $970000.0, up 22.17% from the prior year.
• Raw Materials advanced to $1.2 million in Q1 2026 per GYRE's latest filing, from $970000.0 in the prior quarter.
• Over five years, Raw Materials peaked at $1.2 million in Q2 2025 and troughed at $724000.0 in Q1 2024.
• A 5-year average of $1.0 million and a median of $1.1 million in 2022 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2024 and 2025: Raw Materials slipped 13.6% in 2024, then jumped 61.46% in 2025.
• A 5-year view of Raw Materials shows it stood at $1.1 million in 2022, then dropped by 12.97% to $919000.0 in 2023, then dropped by 13.6% to $794000.0 in 2024, then grew by 22.17% to $970000.0 in 2025, then climbed by 21.03% to $1.2 million in 2026.
• Business Quant data shows GYRE's Raw Materials at $1.2 million in Q1 2026, $970000.0 in Q4 2025, and $1.1 million in Q3 2025.